Leech extract alleviates idiopathic pulmonary fibrosis by TGF-β1/Smad3 signaling pathway

被引:6
作者
Zhang, Yin [1 ]
Lu, Yong-Bo [1 ]
Zhu, Wei-Jie [2 ]
Gong, Xiao-Xi [1 ]
Qian, Rui [1 ]
Lu, Yi-Jing [1 ]
Li, Yu [2 ]
Yao, Wei-Feng [1 ]
Bao, Bei-Hua [1 ]
Zhang, Yi [1 ]
Zhang, Li [1 ,3 ]
Cheng, Fang -Fang [1 ,3 ]
机构
[1] Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resourc, Jiangsu Key Lab High Technol Res TCM Formulae, Natl & Local Collaborat Engn Ctr Chinese Med Resou, Nanjing 210023, Peoples R China
[2] Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Nanjing 210023, Peoples R China
[3] Nanjing Univ Chinese Med, Jiangsu Key Lab High Technol Res TCM Formulae, 138 Xianlin Rd, Nanjing 210023, Peoples R China
基金
中国国家自然科学基金;
关键词
Leech; The leech extract group with molecular weight greater than 10 KDa; Idiopathic pulmonary fibrosis; TGF-beta 1/Smad3 signaling pathway; Pyruvate kinase M2; TGF-BETA; PYRUVATE-KINASE; REGULATOR; BLEOMYCIN; M2;
D O I
10.1016/j.jep.2024.117737
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Leech, as a traditional Chinese medicine for the treatment of blood circulation and blood stasis, was also widely used to cure pulmonary fibrosis in China. In clinical practice, some traditional Chinese medicine preparation such as Shui Zhi Xuan Bi Hua Xian Tang and Shui Zhi Tong Luo Capsule composed of leech, could improve the clinical symptoms and pulmonary function in patients with idiopathic pulmonary fibrosis (IPF). However, the material basis of the leech in the treatment of IPF were not yet clear. Aim of the study: Screen out the components of leech that have the anti-pulmonary fibrosis effects, and further explore the therapeutic mechanism of the active components. Materials and methods: In this study, the different molecular weight components of leech extract samples were prepared using the semi-permeable membranes with different pore sizes. The therapeutic effects of the leech extract groups with molecular weight greater than 10 KDa (>10 KDa group), between 3 KDa and 10 KDa (3-10 KDa group), and less than 3 KDa (<3 KDa group) on pulmonary fibrosis were firstly investigated by cell proliferation and cytotoxicity assay (MTT), cell wound healing assay, immunofluorescence staining (IF) and Western blot (WB) assay through the TGF-beta 1-induced fibroblast cell model. Then bleomycin-induced pulmonary fibrosis (BML-induced PF) mouse model was constructed to investigate the pharmacological activities of the active component group of leech extract in vivo. Pathological changes of the mouse lung were observed by hematoxylineosin staining (H&E) and Masson's trichrome staining (Masson). The hydroxyproline (HYP) content of lung tissues was quantified by HYP detection kit. The levels of extracellular matrix-related fibronectin (FN) and collagen type I (Collagen I), pyruvate kinase M2 (PKM2) monomer and Smad7 protein were determined via WB method. PKM2 and Smad7 protein were further characterized by IF assays. Results: Using TGF-beta 1-induced HFL1 cell line as a PF cell model, the in vitro results demonstrated that the >10 KDa group could significantly inhibited the cell proliferation and migration, downregulated the expression level of cytoskeletal protein vimentin and alpha-smooth muscle actin (alpha-SMA), and reduced the deposition of FN and Collagen I. In the BML-induced PF mouse model, the >10 KDa group significantly reduced the content of HYP, downregulated the expression levels of FN and Collagen I in lung tissues, and delayed the pathological changes of lung tissue structure. The results of WB and IF assays further indicated that the >10 KDa group could up-regulate the expression level of PKM2 monomer and Smad7 protein in the cellular level, thereby delaying the progression of pulmonary fibrosis. Conclusions: Our study revealed that the >10 KDa group was the main material basis of the leech extract that inhibited pulmonary fibrosis through TGF-beta 1/Smad3 signaling pathway.
引用
收藏
页数:11
相关论文
共 73 条
[41]   Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis [J].
Mei, Qianru ;
Liu, Zhe ;
Zuo, He ;
Yang, Zhenhua ;
Qu, Jing .
FRONTIERS IN PHARMACOLOGY, 2022, 12
[42]   TGF-β: the master regulator of fibrosis [J].
Meng, Xiao-ming ;
Nikolic-Paterson, David J. ;
Lan, Hui Yao .
NATURE REVIEWS NEPHROLOGY, 2016, 12 (06) :325-338
[43]   Longitudinal Changes in Clinical Features, Management, and Outcomes of Idiopathic Pulmonary Fibrosis A Nationwide Cohort Study [J].
Moon, Sung Woo ;
Kim, Song Yee ;
Chung, Man Pyo ;
Yoo, Hongseok ;
Jeong, Sung Hwan ;
Kim, Dong Soon ;
Song, Jin Woo ;
Lee, Hong Lyeol ;
Choi, Sun Mi ;
Kim, Young Whan ;
Kim, Yong Hyun ;
Park, Choon-Sik ;
Park, Sung-Woo ;
Park, Jong Sun ;
Jegal, Yangjin ;
Lee, Jongmin ;
Uh, Soo-Taek ;
Kim, Tae-Hyung ;
Lee, Jae Ha ;
Kim, Yee Hyung ;
Shin, Bumsu ;
Lee, Hyun-kyung ;
Yang, Sei-Hoon ;
Lee, Hyun ;
Kim, Sang-Heon ;
Lee, Eun-Joo ;
Choi, Hye Sook ;
Shin, Hyejung ;
Park, Yong Bum ;
Shin, Jong Wook ;
Park, Moo Suk .
ANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (05) :780-787
[44]   Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis [J].
Moss, Benjamin J. ;
Ryter, Stefan W. ;
Rosas, Ivan O. .
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2022, 17 :515-546
[45]   Hepatocyte FoxO1 Deficiency Protects From Liver Fibrosis via Reducing Inflammation and TGF-β1-mediated HSC Activation [J].
Pan, Quan ;
Gao, Mingming ;
Kim, Dami ;
Ai, Weiqi ;
Yang, Wanbao ;
Jiang, Wen ;
Brashear, Wesley ;
Dai, Yujiao ;
Li, Sha ;
Sun, Yuxiang ;
Qi, Yajuan ;
Guo, Shaodong .
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 2024, 17 (01) :41-58
[46]   Pirfenidone protects against paraquat-induced lung injury and fibrosis in mice by modulation of inflammation, oxidative stress, and gene expression [J].
Pourgholamhossein, Fateme ;
Rasooli, Rokhsana ;
Pournamdari, Mostafa ;
Pourgholi, Leyla ;
Samareh-Fekri, Mitra ;
Ghazi-Khansari, Mahmoud ;
Iranpour, Maryam ;
Poursalehi, Hamid-Reza ;
Heidari, Mahmoud-Reza ;
Mandegary, Ali .
FOOD AND CHEMICAL TOXICOLOGY, 2018, 112 :39-46
[47]   Honokiol: A polyphenol neolignan ameliorates pulmonary fibrosis by inhibiting TGF-β/Smad signaling, matrix proteins and IL-6/CD44/STAT3 axis both in vitro and in vivo [J].
Pulivendala, Gauthami ;
Bale, Swarna ;
Godugu, Chandraiah .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 391
[48]   Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline [J].
Raghu, Ganesh ;
Remy-Jardin, Martine ;
Richeldi, Luca ;
Thomson, Carey C. ;
Inoue, Yoshikazu ;
Johkoh, Takeshi ;
Kreuter, Michael ;
Lynch, David A. ;
Maher, Toby M. ;
Martinez, Fernando J. ;
Molina-Molina, Maria ;
Myers, Jeffrey L. ;
Nicholson, Andrew G. ;
Ryerson, Christopher J. ;
Strek, Mary E. ;
Troy, Lauren K. ;
Wijsenbeek, Marlies ;
Mammen, Manoj J. ;
Hossain, Tanzib ;
Bissell, Brittany D. ;
Herman, Derrick D. ;
Hon, Stephanie M. ;
Kheir, Fayez ;
Khor, Yet H. ;
Macrea, Madalina ;
Antoniou, Katerina M. ;
Bouros, Demosthenes ;
Buendia-Roldan, Ivette ;
Caro, Fabian ;
Crestani, Bruno ;
Ho, Lawrence ;
Morisset, Julie ;
Olson, Amy L. ;
Podolanczuk, Anna ;
Poletti, Venerino ;
Selman, Moises ;
Ewing, Thomas ;
Jones, Stephen ;
Knight, Shandra L. ;
Ghazipura, Marya ;
Wilson, Kevin C. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205 (09) :E18-E47
[49]   TGF-β Signaling in Lung Health and Disease [J].
Saito, Akira ;
Horie, Masafumi ;
Nagase, Takahide .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (08)
[50]   Therapeutic effects of the rhSOD2-Hirudin fusion protein on bleomycin-induced pulmonary fibrosis in mice [J].
Shen, Lianghua ;
Lei, Sijia ;
Huang, Luyuan ;
Li, Shuaiguang ;
Yi, Shanze ;
Breitzig, Mason ;
Huang, Meiyan ;
Mo, Xuemei ;
Sun, Hanxiao ;
Zheng, Qing ;
Tian, Jianing ;
Czachor, Alexander ;
Wang, Feng .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 852 :77-89